Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...
The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the ...
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.
For a majority of people, the COVID vaccine doesn’t cause adverse health effects — but a small percentage experience chronic ...
A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...
A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...